Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ROSG's Cash to Debt is ranked higher than
90% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. ROSG: No Debt )
ROSG' s 10-Year Cash to Debt Range
Min: 0.77   Max: No Debt
Current: No Debt

Equity to Asset 0.91
ROSG's Equity to Asset is ranked higher than
94% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ROSG: 0.91 )
ROSG' s 10-Year Equity to Asset Range
Min: -0.27   Max: 0.95
Current: 0.91

-0.27
0.95
F-Score: 4
Z-Score: 2.60
M-Score: -2.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1816.84
ROSG's Operating margin (%) is ranked lower than
53% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ROSG: -1816.84 )
ROSG' s 10-Year Operating margin (%) Range
Min: -9864.67   Max: -3295.56
Current: -1816.84

-9864.67
-3295.56
Net-margin (%) -1800.00
ROSG's Net-margin (%) is ranked lower than
53% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. ROSG: -1800.00 )
ROSG' s 10-Year Net-margin (%) Range
Min: -11003.33   Max: -3184.44
Current: -1800

-11003.33
-3184.44
ROE (%) -57.89
ROSG's ROE (%) is ranked higher than
54% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. ROSG: -57.89 )
ROSG' s 10-Year ROE (%) Range
Min: -545.27   Max: -47.3
Current: -57.89

-545.27
-47.3
ROA (%) -53.14
ROSG's ROA (%) is ranked higher than
52% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. ROSG: -53.14 )
ROSG' s 10-Year ROA (%) Range
Min: -286.59   Max: -40.87
Current: -53.14

-286.59
-40.87
ROC (Joel Greenblatt) (%) -1768.36
ROSG's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. ROSG: -1768.36 )
ROSG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1879.86   Max: -966.63
Current: -1768.36

-1879.86
-966.63
Revenue Growth (%) -65.70
ROSG's Revenue Growth (%) is ranked higher than
51% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. ROSG: -65.70 )
ROSG' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -57.7
Current: -65.7

EBITDA Growth (%) -68.90
ROSG's EBITDA Growth (%) is ranked lower than
52% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. ROSG: -68.90 )
ROSG' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -4.6
Current: -68.9

EPS Growth (%) -68.90
ROSG's EPS Growth (%) is ranked lower than
53% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ROSG: -68.90 )
ROSG' s 10-Year EPS Growth (%) Range
Min: -68.9   Max: 45.9
Current: -68.9

-68.9
45.9
» ROSG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.34
ROSG's P/B is ranked higher than
93% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. ROSG: 1.34 )
ROSG' s 10-Year P/B Range
Min: 0.73   Max: 4.84
Current: 1.34

0.73
4.84
P/S 75.50
ROSG's P/S is ranked lower than
60% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.90 vs. ROSG: 75.50 )
ROSG' s 10-Year P/S Range
Min: 3.33   Max: 209.09
Current: 75.5

3.33
209.09
EV-to-EBIT -0.71
ROSG's EV-to-EBIT is ranked higher than
51% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ROSG: -0.71 )
ROSG' s 10-Year EV-to-EBIT Range
Min: -2.6   Max: 2.4
Current: -0.71

-2.6
2.4
Current Ratio 12.90
ROSG's Current Ratio is ranked higher than
95% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ROSG: 12.90 )
ROSG' s 10-Year Current Ratio Range
Min: 0.65   Max: 25.08
Current: 12.9

0.65
25.08
Quick Ratio 12.90
ROSG's Quick Ratio is ranked higher than
95% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. ROSG: 12.90 )
ROSG' s 10-Year Quick Ratio Range
Min: 0.65   Max: 25.08
Current: 12.9

0.65
25.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.43
ROSG's Price/Net Cash is ranked higher than
99% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ROSG: 1.43 )
ROSG' s 10-Year Price/Net Cash Range
Min: 1.31   Max: 7.58
Current: 1.43

1.31
7.58
Price/Net Current Asset Value 1.41
ROSG's Price/Net Current Asset Value is ranked higher than
99% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ROSG: 1.41 )
ROSG' s 10-Year Price/Net Current Asset Value Range
Min: 1.31   Max: 7
Current: 1.41

1.31
7
Price/Tangible Book 1.33
ROSG's Price/Tangible Book is ranked higher than
96% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. ROSG: 1.33 )
ROSG' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 3.68
Current: 1.33

1.02
3.68
Price/Median PS Value 1.05
ROSG's Price/Median PS Value is ranked higher than
67% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ROSG: 1.05 )
ROSG' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 2.23
Current: 1.05

0.19
2.23
Earnings Yield (Greenblatt) -140.80
ROSG's Earnings Yield (Greenblatt) is ranked lower than
127% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. ROSG: -140.80 )
ROSG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 41.5   Max: 2915.2
Current: -140.8

41.5
2915.2
Forward Rate of Return (Yacktman) -774.76
ROSG's Forward Rate of Return (Yacktman) is ranked lower than
55% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.68 vs. ROSG: -774.76 )
ROSG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2244.7   Max: -79.9
Current: -774.76

-2244.7
-79.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RQ1.Germany
Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.
» More Articles for NAS:ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics Reports Second Quarter Financial Results, Provides Business Update Sep 08 2009 
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd. Jan 08 2009 
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Nasdaq stocks posting largest volume increases Oct 24 2014
Rosetta Genomics' microRNA-based assay for Thyroid Cancer Highlighted in Poster Presentation at 84th... Oct 23 2014
Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of... Oct 21 2014
Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of... Oct 21 2014
Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells Oct 13 2014
ROSG: Rosetta Genomics Reports Better Than Expected Financial Results for 1H2014 Sep 19 2014
Half Year 2014 Rosetta Genomics Ltd Earnings Release - Time Not Supplied Sep 18 2014
Rosetta Genomics Reports Financial Results for the First Half of 2014 Sep 17 2014
Rosetta Genomics to Host Business Update Conference Call on September 18, 2014 Sep 10 2014
Rosetta Genomics Initiates Post-Marketing Registry Study of Its Cancer Origin Test Sep 03 2014
Rosetta Genomics to Participate in September Investor Conferences Sep 02 2014
Rosetta Genomics and Moffitt Cancer Center Enter Into Strategic Alliance to Develop microRNA-Based... Sep 02 2014
Rosetta Genomics Expands Management Team With Appointment of Douglas Sites as Executive Vice... Aug 18 2014
Rosetta Genomics Announces Agreement With Global Pharmaceutical Company to Advance Efforts in... Jul 31 2014
Rosetta Genomics Announces Next-Generation Sequencing Research Collaboration With Weizmann Institute... Jul 29 2014
Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test Jul 22 2014
Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer Jul 10 2014
ROSG: Collaboration Accelerates Product Development and Represents New Avenue for Revenue Growth Jun 27 2014
Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of... Jun 26 2014
UPDATE: Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of... Jun 09 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK